Australia
· Delayed Price · Currency is AUD Australian Clinical Labs Statistics
Total Valuation
ASX:ACL has a market cap or net worth of AUD 544.17 million. The enterprise value is 838.31 million.
| Market Cap | 544.17M |
| Enterprise Value | 838.31M |
Important Dates
The next estimated earnings date is Tuesday, August 26, 2025.
| Earnings Date | Aug 26, 2025 |
| Ex-Dividend Date | Mar 27, 2025 |
Share Statistics
ASX:ACL has 194.35 million shares outstanding. The number of shares has decreased by -0.78% in one year.
| Current Share Class | 194.35M |
| Shares Outstanding | 194.35M |
| Shares Change (YoY) | -0.78% |
| Shares Change (QoQ) | +2.12% |
| Owned by Insiders (%) | 1.86% |
| Owned by Institutions (%) | 74.67% |
| Float | 176.02M |
Valuation Ratios
The trailing PE ratio is 18.23 and the forward PE ratio is 14.76. ASX:ACL's PEG ratio is 0.78.
| PE Ratio | 18.23 |
| Forward PE | 14.76 |
| PS Ratio | 0.75 |
| PB Ratio | 3.22 |
| P/TBV Ratio | 139.82 |
| P/FCF Ratio | 3.39 |
| P/OCF Ratio | 3.26 |
| PEG Ratio | 0.78 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.21, with an EV/FCF ratio of 5.22.
| EV / Earnings | 27.33 |
| EV / Sales | 1.15 |
| EV / EBITDA | 4.21 |
| EV / EBIT | 12.62 |
| EV / FCF | 5.22 |
Financial Position
The company has a current ratio of 0.59, with a Debt / Equity ratio of 1.86.
| Current Ratio | 0.59 |
| Quick Ratio | 0.45 |
| Debt / Equity | 1.86 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | 1.96 |
| Interest Coverage | 3.61 |
Financial Efficiency
Return on equity (ROE) is 18.56% and return on invested capital (ROIC) is 8.51%.
| Return on Equity (ROE) | 18.56% |
| Return on Assets (ROA) | 7.11% |
| Return on Invested Capital (ROIC) | 8.51% |
| Return on Capital Employed (ROCE) | 17.62% |
| Revenue Per Employee | 148,627 |
| Profits Per Employee | 6,259 |
| Employee Count | 4,900 |
| Asset Turnover | 1.25 |
| Inventory Turnover | 27.75 |
Taxes
In the past 12 months, ASX:ACL has paid 15.30 million in taxes.
| Income Tax | 15.30M |
| Effective Tax Rate | 33.03% |
Stock Price Statistics
The stock price has increased by +9.38% in the last 52 weeks. The beta is 1.08, so ASX:ACL's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +9.38% |
| 50-Day Moving Average | 2.93 |
| 200-Day Moving Average | 3.32 |
| Relative Strength Index (RSI) | 50.04 |
| Average Volume (20 Days) | 1,126,801 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:ACL had revenue of AUD 728.27 million and earned 30.67 million in profits. Earnings per share was 0.15.
| Revenue | 728.27M |
| Gross Profit | 265.75M |
| Operating Income | 66.44M |
| Pretax Income | 46.31M |
| Net Income | 30.67M |
| EBITDA | 79.99M |
| EBIT | 66.44M |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
The company has 21.57 million in cash and 315.32 million in debt, giving a net cash position of -293.75 million or -1.51 per share.
| Cash & Cash Equivalents | 21.57M |
| Total Debt | 315.32M |
| Net Cash | -293.75M |
| Net Cash Per Share | -1.51 |
| Equity (Book Value) | 169.11M |
| Book Value Per Share | 0.85 |
| Working Capital | -85.67M |
Cash Flow
In the last 12 months, operating cash flow was 167.16 million and capital expenditures -6.68 million, giving a free cash flow of 160.47 million.
| Operating Cash Flow | 167.16M |
| Capital Expenditures | -6.68M |
| Free Cash Flow | 160.47M |
| FCF Per Share | 0.83 |
Margins
Gross margin is 36.49%, with operating and profit margins of 9.12% and 4.21%.
| Gross Margin | 36.49% |
| Operating Margin | 9.12% |
| Pretax Margin | 6.36% |
| Profit Margin | 4.21% |
| EBITDA Margin | 10.98% |
| EBIT Margin | 9.12% |
| FCF Margin | 22.03% |
Dividends & Yields
This stock pays an annual dividend of 0.12, which amounts to a dividend yield of 4.41%.
| Dividend Per Share | 0.12 |
| Dividend Yield | 4.41% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 77.78% |
| Buyback Yield | 0.78% |
| Shareholder Yield | 5.17% |
| Earnings Yield | 5.64% |
| FCF Yield | 29.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ASX:ACL has an Altman Z-Score of 2.65 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 7 |